About Achieve Life Sciences, Inc.
https://www.achievelifesciences.comAchieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
CEO
Richard A. B. Stewart
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-07-31 | Reverse | 1:20 |
| 2018-05-24 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
PROPEL BIO MANAGEMENT, LLC
Shares:3.79M
Value:$21.24M
ALYESKA INVESTMENT GROUP, L.P.
Shares:3.5M
Value:$19.66M
VANGUARD GROUP INC
Shares:2.46M
Value:$13.81M
Summary
Showing Top 3 of 76
About Achieve Life Sciences, Inc.
https://www.achievelifesciences.comAchieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $14.69M ▲ | $-14.44M ▼ | 0% | $-0.28 ▲ | $-14.19M ▼ |
| Q2-2025 | $0 | $12.56M ▼ | $-12.72M ▲ | 0% | $-0.37 | $-12.47M ▲ |
| Q1-2025 | $0 | $12.89M ▲ | $-12.83M ▼ | 0% | $-0.37 ▼ | $-12.58M ▼ |
| Q4-2024 | $0 | $12.19M ▼ | $-12.36M ▲ | 0% | $-0.36 | $-12.11M ▼ |
| Q3-2024 | $0 | $12.47M | $-12.51M | 0% | $-0.36 | $-12.09M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $48.11M ▼ | $52.04M ▼ | $18.43M ▲ | $33.62M ▼ |
| Q2-2025 | $55.4M ▲ | $58.94M ▲ | $17.27M ▲ | $41.67M ▲ |
| Q1-2025 | $23.25M ▼ | $27.36M ▼ | $17.08M ▼ | $10.28M ▼ |
| Q4-2024 | $34.34M ▼ | $38.63M ▼ | $17.73M ▲ | $20.9M ▼ |
| Q3-2024 | $42.91M | $47.92M | $16.54M | $31.38M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-14.44M ▼ | $-11.33M ▼ | $-12.65M ▼ | $4.04M ▼ | $-19.94M ▼ | $-11.33M ▼ |
| Q2-2025 | $-12.72M ▲ | $-9.07M ▲ | $6.7M ▼ | $41.22M ▲ | $38.86M ▲ | $-9.07M ▲ |
| Q1-2025 | $-12.83M ▼ | $-11.09M ▼ | $11.35M ▼ | $0 ▼ | $263K ▼ | $-11.09M ▼ |
| Q4-2024 | $-12.36M ▲ | $-9.19M ▲ | $11.72M ▼ | $682K ▲ | $3.21M ▲ | $-9.19M ▲ |
| Q3-2024 | $-12.51M | $-10.37M | $13.27M | $-8.11M | $-5.21M | $-10.37M |
CEO
Richard A. B. Stewart
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-07-31 | Reverse | 1:20 |
| 2018-05-24 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
PROPEL BIO MANAGEMENT, LLC
Shares:3.79M
Value:$21.24M
ALYESKA INVESTMENT GROUP, L.P.
Shares:3.5M
Value:$19.66M
VANGUARD GROUP INC
Shares:2.46M
Value:$13.81M
Summary
Showing Top 3 of 76